Business Context and Reporting Period
Company: Astro-Med, Inc. (Note: Input metadata referenced "Astronova, Inc.", but the filing text identifies the registrant as Astro-Med, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: May 5, 2001
Business Overview: The company operates in three primary product groups: Grass-Telefactor (neurophysiology), QuickLabel Systems (specialty printers), and Test & Measurement (data acquisition). The company is headquartered in West Warwick, Rhode Island.
Key Financial Metrics
| Metric | Q1 2001 (Ended May 5) | Q1 2000 (Ended April 29) |
|---|---|---|
| Net Sales | $12,435,979 | $12,530,201 |
| Gross Profit | $5,052,093 | $5,169,923 |
| Gross Margin | 40.6% | 41.3% |
| Operating Income | $16,493 | $169,755 |
| Net Income | $149,675 | $157,860 |
| Diluted EPS | $0.04 | $0.04 |
| Cash from Operations | $293,731 | ($2,137,968) |
| Cash & Equivalents (End) | $1,613,564 | $1,288,952 |
| Total Debt (Current + Long-Term) | $60,227 | N/A |
Material Changes vs. Prior Period
- Sales: Net sales decreased slightly by less than 1% ($94,000) compared to the prior year. Domestic sales were flat, while international sales declined 2% due to a strengthening U.S. dollar, despite a 6% increase in local currency terms.
- Product Mix: Grass-Telefactor sales increased 6% driven by research supplies. QuickLabel Systems (QLS) sales fell 2% due to lower hardware sales. Test & Measurement (T&M) sales dropped 7%, primarily due to international channel weakness.
- Profitability: Operating income declined significantly by approximately 90% ($153,000) to $16,493. Gross margin compressed to 40.6% from 41.3% due to product mix shifts and lower margins in the T&M segment.
- Expenses: Selling, General, and Administrative (SG&A) expenses rose 6% to $4.13 million, attributed to higher international dealer commissions. Research and Development (R&D) spending decreased 17% to $909,000.
- Cash Flow: Operating cash flow improved dramatically from a use of $2.14 million in the prior year to a generation of $294,000, driven by a $1.6 million improvement in accounts receivable collection.
Guidance, Outlook, and Risks
Management Commentary:
- Inventory Build: Inventory increased to $11.35 million (from $10.78 million) in anticipation of new product launches (Dash 18 and Pronto lines), causing inventory turns to decline to 2.2 times.
- Capital Expenditures: The company spent $357,000 on machinery, IT hardware, and tooling.
- Dividends: A cash dividend of $0.04 per share was declared and paid.
- One-Time Item: Other income included a $125,000 gain from the settlement of litigation regarding a contract dispute.
Risks and Contingencies:
- Declining demand in defense and aerospace sectors affecting the Test & Measurement market.
- Competition in specialty printers, data acquisition, and neurophysiology industries.
- Foreign currency exchange rate fluctuations impacting international results.
- Ability to successfully integrate acquisitions and gain market acceptance for new QLS color printer products.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 6% local currency growth in international sales versus the reported 2% USD decline.
- Inventory Levels: Monitor the $11.35 million inventory balance to ensure the build-up for Dash 18 and Pronto launches converts to sales without significant write-downs.
- Margin Pressure: Assess whether the decline in T&M margins is a temporary product mix issue or a structural competitive threat.
- Working Capital: Confirm the improvement in the collection cycle (down to 62 days) is maintained in subsequent quarters.
- Debt Obligations: Note the low total debt level ($60k) but verify any off-balance-sheet commitments or lease obligations not detailed in the summary.